GT201400034A - Compuestos y composiciones como inhibidores de la quinasa c-kit - Google Patents

Compuestos y composiciones como inhibidores de la quinasa c-kit

Info

Publication number
GT201400034A
GT201400034A GT201400034A GT201400034A GT201400034A GT 201400034 A GT201400034 A GT 201400034A GT 201400034 A GT201400034 A GT 201400034A GT 201400034 A GT201400034 A GT 201400034A GT 201400034 A GT201400034 A GT 201400034A
Authority
GT
Guatemala
Prior art keywords
compounds
kit
quinase
inhibitors
compositions
Prior art date
Application number
GT201400034A
Other languages
English (en)
Spanish (es)
Inventor
Molteni Valentina
Petrassi Hank Michael James
Li Xiaolin
Liu Xiaodong
Loren Jon
Nabakka Juliet
Nguyen Bao
Yeh Vince
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201400034A publication Critical patent/GT201400034A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
GT201400034A 2011-09-01 2014-02-27 Compuestos y composiciones como inhibidores de la quinasa c-kit GT201400034A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161530038P 2011-09-01 2011-09-01

Publications (1)

Publication Number Publication Date
GT201400034A true GT201400034A (es) 2015-02-19

Family

ID=46829904

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400034A GT201400034A (es) 2011-09-01 2014-02-27 Compuestos y composiciones como inhibidores de la quinasa c-kit

Country Status (30)

Country Link
US (3) US8569283B2 (enExample)
EP (1) EP2751104B1 (enExample)
JP (1) JP6134319B2 (enExample)
KR (1) KR101962495B1 (enExample)
CN (1) CN103797011B (enExample)
AP (1) AP2014007493A0 (enExample)
AR (1) AR087753A1 (enExample)
AU (1) AU2012302042B2 (enExample)
BR (1) BR112014004560A2 (enExample)
CA (1) CA2845169C (enExample)
CL (1) CL2014000492A1 (enExample)
CO (1) CO6900141A2 (enExample)
CR (1) CR20140107A (enExample)
CU (1) CU20140024A7 (enExample)
EA (1) EA026152B1 (enExample)
ES (1) ES2761332T3 (enExample)
GT (1) GT201400034A (enExample)
IL (1) IL231227A0 (enExample)
MA (1) MA35460B1 (enExample)
MX (1) MX339937B (enExample)
PE (1) PE20140909A1 (enExample)
PH (1) PH12014500372A1 (enExample)
PL (1) PL2751104T3 (enExample)
PT (1) PT2751104T (enExample)
SG (1) SG2014014369A (enExample)
TN (1) TN2014000068A1 (enExample)
TW (1) TW201313717A (enExample)
UY (1) UY34301A (enExample)
WO (1) WO2013033167A1 (enExample)
ZA (1) ZA201401175B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9199981B2 (en) * 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
WO2013033167A1 (en) 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
CN109568319A (zh) 2013-01-10 2019-04-05 普尔莫凯恩股份有限公司 非选择性激酶抑制剂
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2015054574A1 (en) 2013-10-11 2015-04-16 Zisman Lawrence S Spray dry formulations
US20150288928A1 (en) * 2014-04-08 2015-10-08 Sony Corporation Security camera system use of object location tracking data
CN105384738B (zh) * 2014-08-21 2017-08-29 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
EP4074378A1 (en) 2015-07-02 2022-10-19 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
US10474987B2 (en) * 2015-08-05 2019-11-12 Whirlpool Corporation Object recognition system for an appliance and method for managing household inventory of consumables
WO2017214413A1 (en) * 2016-06-08 2017-12-14 Chrysalis, Inc. Imidazo[1,2-a]pyridine derivatives as histone demethylase inhibitors
KR20190018681A (ko) 2016-06-16 2019-02-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항균제로서의 헤테로고리 화합물
EA201990043A1 (ru) 2016-06-16 2019-05-31 Янссен Сайенсиз Айрлэнд Анлимитед Компани Антибактериальные соединения
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
CN110087653A (zh) 2016-10-27 2019-08-02 普尔莫凯恩股份有限公司 用于治疗肺高血压的组合疗法
US20180162291A1 (en) * 2016-12-12 2018-06-14 Wipro Limited System and method of dynamically adjusting field of view of an image capturing device
EP4417262A3 (en) 2017-03-01 2024-11-27 Janssen Sciences Ireland Unlimited Company Combination therapy
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
KR102625224B1 (ko) * 2018-10-31 2024-01-15 주식회사 큐로젠 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
AU2020274564A1 (en) * 2019-05-13 2021-12-09 Novartis Ag Crystalline forms of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide
WO2021035788A1 (zh) 2019-08-29 2021-03-04 中国科学院合肥物质科学研究院 吡唑衍生物及其用途
KR102955654B1 (ko) 2019-09-13 2026-04-21 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항균 화합물
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
MX2022007044A (es) 2019-12-13 2022-06-24 Nippon Shinyaku Co Ltd Compuesto y composicion como inhibidor de cinasa del receptor de los factores de crecimiento derivados de las plaquetas (pdgf).
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022016021A1 (en) 2020-07-15 2022-01-20 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
TW202237097A (zh) * 2020-11-19 2022-10-01 美商第三諧波生物公司 選擇性ｃ－ｋｉｔ激酶抑制劑之醫藥組合物及其製造及使用方法
KR20230157400A (ko) 2021-03-16 2023-11-16 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항박테리아성 화합물
CA3212074A1 (en) 2021-03-17 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022194905A1 (en) 2021-03-17 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
TW202325274A (zh) 2021-10-28 2023-07-01 愛爾蘭商健生科學愛爾蘭無限公司 抗菌化合物
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2024118887A1 (en) 2022-11-30 2024-06-06 Blueprint Medicines Corporation N-phenyl-pyrazolo[1,5-a]pyridine-3-carboxamide derivatives as wild type c-kit kinase inhibitors for the treatment of urticaria
JP2025541190A (ja) * 2022-12-07 2025-12-18 サード ハーモニック バイオ， インコーポレイテッド Ｃ－ｋｉｔキナーゼ阻害剤としての化合物及び組成物
WO2024123966A1 (en) * 2022-12-07 2024-06-13 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
WO2025072330A1 (en) * 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Kit inhibitor compounds and methods of use thereof
WO2025256552A1 (zh) * 2024-06-11 2025-12-18 上海翰森生物医药科技有限公司 吡唑类衍生物抑制剂、其制备方法和应用
WO2025256609A1 (en) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
WO2025259929A1 (en) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004001903A2 (en) 2002-06-20 2003-12-31 Beacon Looms, Inc. Knitted electrical conductor fabric
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
BRPI0515081B8 (pt) 2004-09-09 2021-05-25 Natco Pharma Ltd composto, processo para a preparação de um sal de guanidino trifluormetilaroil amida, processo para a preparação de um fenil amino pirido pirimidina, composições farmacêuticas e processos para preparar (3,5-bis trifluormetil)-n-[4-metil-3-(4-piridin-3-il-pirimidin-2-ilamino)-fenil]-benzamida
WO2006071940A2 (en) 2004-12-23 2006-07-06 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
US7754717B2 (en) * 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
AU2007317349B2 (en) * 2006-11-03 2011-10-20 Irm Llc Compounds and compositions as protein kinase inhibitors
MX2013005454A (es) * 2010-11-15 2013-06-24 Abbvie Inc Inhibidores de nampt y rock.
US20130023751A1 (en) 2011-07-18 2013-01-24 Samuel Victor Lichtenstein Water retention monitoring
JP2014525462A (ja) 2011-09-01 2014-09-29 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｐｄｇｆｒキナーゼ阻害剤としての化合物および組成物
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
BR112014003963A2 (pt) 2011-09-01 2017-03-21 Irm Llc compostos e composições como inibidores de quinase c-kit
WO2013033167A1 (en) 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors

Also Published As

Publication number Publication date
EA026152B1 (ru) 2017-03-31
AR087753A1 (es) 2014-04-16
CN103797011B (zh) 2016-03-30
US20140228347A1 (en) 2014-08-14
KR101962495B1 (ko) 2019-03-26
CL2014000492A1 (es) 2014-10-03
BR112014004560A2 (pt) 2017-04-04
SG2014014369A (en) 2014-09-26
MX2014002484A (es) 2014-11-25
PH12014500372A1 (en) 2014-04-07
PL2751104T3 (pl) 2020-04-30
PE20140909A1 (es) 2014-07-20
PT2751104T (pt) 2019-12-16
AU2012302042A1 (en) 2014-04-17
UY34301A (es) 2013-04-05
AU2012302042B2 (en) 2016-03-31
AP2014007493A0 (en) 2014-03-31
CA2845169C (en) 2022-04-19
EP2751104B1 (en) 2019-09-25
CO6900141A2 (es) 2014-03-20
TW201313717A (zh) 2013-04-01
US9023839B2 (en) 2015-05-05
US20140031333A1 (en) 2014-01-30
ES2761332T3 (es) 2020-05-19
TN2014000068A1 (en) 2015-07-01
ZA201401175B (en) 2015-01-28
MA35460B1 (fr) 2014-09-01
CA2845169A1 (en) 2013-03-07
EA201490545A1 (ru) 2014-07-30
US8569283B2 (en) 2013-10-29
MX339937B (es) 2016-06-17
CU20140024A7 (es) 2014-04-24
US20130059832A1 (en) 2013-03-07
CR20140107A (es) 2014-05-02
JP2014525448A (ja) 2014-09-29
US8754071B2 (en) 2014-06-17
KR20140075692A (ko) 2014-06-19
IL231227A0 (en) 2014-04-30
JP6134319B2 (ja) 2017-05-24
EP2751104A1 (en) 2014-07-09
CN103797011A (zh) 2014-05-14
WO2013033167A1 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
ECSP23004573A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
GT201400036A (es) Compuestos y composiciones como inhibidores de la quinasa c - kit
CU20140024A7 (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
CU20140139A7 (es) Compuestos y composiciones para modular la actividad de egfr
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
ECSP13012869A (es) Compuestos y métodos para la modulación de quinasas e indicaciones para los mismos
MX2015012867A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
DOP2014000233A (es) Compuestos de microarn y métodos de modulación de la actividad de mir-21
MX382607B (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa.
MX374452B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
CR20170478A (es) Compuestos novedosos
ECSP14013159A (es) Compuestos inhibidores de metaloenzimas
NI201600071A (es) Compuestos de inhibidor de autotaxina
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
MX2013012896A (es) Compuestos novedosos como moduladores de proteina cinasas.
MX351028B (es) Determinadadas entidades, composiciones y metodos quimicos.
EA201490542A1 (ru) Соединения и композиции в качестве pdgfr киназных ингибиторов
MX2019001011A (es) Compuestos farmaceuticos.
EA201692143A1 (ru) Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы
BR112015000051A2 (pt) tratamento de distúrbios inflamatórios da pele
MX2015003701A (es) Composiciones para tratamiento.
CR20140289A (es) Derivados de quinolina como inhibidores de la enzima pde10a
MX2013011184A (es) Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades.